ORAL S-ADENOSYLMETHIONINE IN PRIMARY FIBROMYALGIA - DOUBLE-BLIND CLINICAL-EVALUATION
ORAL S-ADENOSYLMETHIONINE IN PRIMARY FIBROMYALGIA - DOUBLE-BLIND CLINICAL-EVALUATION
复制标题
DOI：
10.3109/03009749109096803
复制
发表时间：
1991-01-01
影响因子：
2.1
通讯作者：
ANDERSEN, RB
中科院分区：
文献类型：
--
作者：
JACOBSEN, S;DANNESKIOLDSAMSOE, B;ANDERSEN, RB
腺苷甲硫氨酸是一种较新的抗炎药，具有镇痛和抗肿瘤作用。 在44例原发性纤维肌痛患者中，在双盲环境中研究了每日口服800 mg S-腺苷甲硫氨酸与安慰剂的疗效，持续6周。 评价压痛点评分、等速肌力、疾病活动度、主观症状（视觉模拟量表）、情绪参数和副作用。 与安慰剂组相比，积极治疗组的临床疾病活动度（P = 0.04）、上周疼痛（P = 0.002）、疲劳（P = 0.02）、晨僵（P = 0.03）和面部量表评估的情绪（P = 0.006）均有所改善。 压痛点评分、等速肌力、Beck抑郁量表评估的情绪和副作用在两个治疗组中没有差异。 腺苷甲硫氨酸对原发性纤维肌痛有一些有益的作用，可能是治疗原发性纤维肌痛的重要选择。
S-adenosylmethionine is a relatively new anti-inflammatory drug with analgesic and anti-depressant effects. Efficacy of 800 mg orally administered s-adenosylmethionine daily versus placebo for six weeks was investigated in 44 patients with primary fibromyalgia in double-blind settings. Tender point score, isokinetic muscle strength, disease activity, subjective symptoms (visual analog scale), mood parameters and side effects were evaluated. Improvements were seen for clinical disease activity (P = 0.04), pain experienced during the last week (P = 0.002), fatigue (P = 0.02), morning stiffness (P = 0.03) and mood evaluated by Face Scale (P = 0.006) in the actively treated group compared to placebo. The tender point score, isokinetic muscle strength, mood evaluated by Beck Depression Inventory and side effects did not differ in the two treatment groups. S-adenosylmethionine has some beneficial effects on primary fibromyalgia and could be an important option in the treatment hereof.